Interventional × Imatinib Mesylate × Dermatologic × Clear all
NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Novartis

Phase 2 Completed
185 enrolled
NCT00025415 2013-02-07

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled